Bolt Biotherapeutics Inc
NASDAQ:BOLT
Balance Sheet
Balance Sheet Decomposition
Bolt Biotherapeutics Inc
Bolt Biotherapeutics Inc
Balance Sheet
Bolt Biotherapeutics Inc
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
14
|
35
|
6
|
27
|
9
|
11
|
7
|
|
| Cash Equivalents |
14
|
35
|
6
|
27
|
9
|
11
|
7
|
|
| Short-Term Investments |
0
|
0
|
17
|
159
|
160
|
91
|
40
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Other Current Assets |
1
|
1
|
3
|
3
|
4
|
4
|
2
|
|
| Total Current Assets |
14
|
36
|
25
|
189
|
173
|
106
|
51
|
|
| PP&E Net |
1
|
12
|
16
|
31
|
29
|
24
|
25
|
|
| PP&E Gross |
1
|
12
|
16
|
31
|
29
|
24
|
25
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
2
|
4
|
6
|
7
|
|
| Long-Term Investments |
0
|
0
|
0
|
85
|
24
|
26
|
23
|
|
| Other Long-Term Assets |
0
|
1
|
5
|
3
|
3
|
4
|
1
|
|
| Total Assets |
16
N/A
|
48
+203%
|
47
-4%
|
308
+562%
|
228
-26%
|
160
-30%
|
100
-38%
|
|
| Liabilities | ||||||||
| Accounts Payable |
1
|
2
|
2
|
4
|
4
|
3
|
2
|
|
| Accrued Liabilities |
2
|
6
|
8
|
15
|
18
|
15
|
11
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
1
|
2
|
3
|
2
|
2
|
3
|
|
| Total Current Liabilities |
3
|
9
|
11
|
21
|
23
|
20
|
16
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
8
|
35
|
36
|
33
|
27
|
27
|
|
| Total Liabilities |
4
N/A
|
17
+367%
|
46
+175%
|
58
+25%
|
56
-2%
|
47
-16%
|
42
-10%
|
|
| Equity | ||||||||
| Common Stock |
28
|
78
|
105
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
17
|
48
|
108
|
207
|
295
|
364
|
427
|
|
| Additional Paid In Capital |
1
|
2
|
4
|
457
|
468
|
477
|
485
|
|
| Other Equity |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Equity |
12
N/A
|
32
+156%
|
0
-99%
|
250
+83 267%
|
172
-31%
|
113
-34%
|
57
-49%
|
|
| Total Liabilities & Equity |
16
N/A
|
48
+203%
|
47
-4%
|
308
+562%
|
228
-26%
|
160
-30%
|
100
-38%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
2
|
2
|
2
|
2
|
2
|
2
|
2
|
|